A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine (VIEW-Iran)

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT03888157

NN2211-4438

U1111-1213-4238 (Other Identifier)

Details and patient eligibility

About

The purpose of the study is to collect information on how the medicine Victoza® (liraglutide) works in people with Type 2 diabetes in Iran. Patients will get Victoza® as prescribed to them by their study doctor. The study will last for about 5 to 8 months. Patients will be asked to complete some questionnaires about their health and diabetes treatment. Patients will complete these during their normally scheduled visits with study doctor.

Enrollment: 839 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
• Male or female, age greater than or equal to 18 years at the time of signing informed consent
• The decision to initiate treatment with commercially available Victoza® has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
• Patients diagnosed with type 2 diabetes mellitus (T2DM), with treatment planned according to the Iranian label for Victoza® at treatment initiation
• Available glycated haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of treatment with Victoza®

Exclusion criteria

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Known or suspected hypersensitivity to Victoza® or related products
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Trial design

839 participants in 1 patient group

Liraglutide

Description:

Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.

Treatment:

Drug: Liraglutide